Regulatory Requirements and Quality Assurance in Development and Manufacturing of Pharmaceutical Products
Syllabus, Master's level, 3FG240
- Code
- 3FG240
- Education cycle
- Second cycle
- Main field(s) of study and in-depth level
- Drug Discovery and Development A1N, Drug Management A1N, Pharmaceutical Sciences A1N
- Grading system
- Pass with distinction (VG), Pass (G), Fail (U)
- Finalised by
- The Educational Board of Pharmacy, 26 May 2016
- Responsible department
- Department of Pharmaceutical Biosciences
General provisions
Substituting and corresponding earlier the course 3FG416 Regulatory Requirements and Quality Assurance in Development and Manufacturing of Pharmaceutical Products.
This course substitutes and corresponds to 3FG840.
Entry requirements
Applicants within the Bachelor of Science Programme in Pharmacy should have 120 credits including the course Pharmaceutics and Pharmaceutical Physical Chemistry and attended all compulsory courses in semesters 1-5 of the programme.
Applicants within the Master of Science Programme in Chemical Engineering should have attended the course Pharmaceutics.
Accepted to the Master Programme in Drug Discovery and Development or the Master Programme in Drug Management with basic education in pharmaceutics.
For the single subject course, a Bachelor's degree in pharmaceutical science or science including knowledge equivalent to 60 credits pharmacy including basic education in pharmaceutics, is required. Other education is assessed individually. Knowledge in Swedish and English equivalent to what that is required for basic eligibility to Swedish first-cycle education.
Learning outcomes
The students should on completion of the course: - be able to find and use the sources to current information about the regulatory requirements that apply to development, documentation and approval of new drugs - be able to describe the processes to receive approval for the use of drugs on man - be able to describe and apply the quality system and working methods that apply to the preparation of drugs in pharmacies and in industrial production of drugs and connected authority control - be able to evaluate documentation of the production and control of drug - be able to describe the basic requirements for activities within drug production as the qualified person
Content
As theme for the course consistently comes the regulatory framework for the development, documentation, production and approval of a new medicinal product will be treated step by step. Thus, the following parts will be treated: 1. Basic concepts about drugs, the pharmaceutical market, the pharmaceutical industry, the development process for new drugs, the approval processes and the supervision by the society. Drug distribution and retail trade. 2. Basic concepts as quality assurance, its different parts, GMP and GLP, GCLP, GCP, etc., will be defined and their role and aims within pharmaceutical activities be explained. 3. The different bodies of the regulatory system, The Medical Products Agency, EMEA, The European Commission and The Council of Europe. The relations between EUs regulations and the Swedish legislation and Sweden's participation in the international network. The role of pharmacopoeia in the control of the quality of drugs. 4. The principles for validation of analytical methods and manufacturing processes as well as requirements and methods for qualification of equipment for production of raw materials and final products. 5. Requirements regarding organisation, documentation, staff, premises and equipment for production of drugs. 6. General principles of the requirements on clinical trial and approval of new drugs of EU, FDA and ICH of and the different procedures for the approval of new drugs within EU. 7. The procedure for the approval of other pharmaceutical groups (herbal drugs, homeopathics etc.) and for other pharmacy related products for example medical-technical products. 8. The continuous follow-up control of approved drugs (central and national), 5-years approval, changes, information specification, epidemiological data etc. Adverse drug reports, WHO Collaborating Centre for International Drug Monitoring. 9. The supervision of the international market for raw materials, control medicines and common products. Internet sale. Control of marketing activities. The pharmacy system. 10. The companies responsibility regarding approved drugs: monitoring of adverse reactions, information, liability and insurance issues. Patents. 11. Case study around documentation of a new drug
Instruction
The teaching is given in the form of lectures, group exercises, project work and study visit. Compulsory parts of the course: Course introduction, group exercises, project work and study visits.
Assessment
Examination takes place at the end of the course. To pass the course is required, apart from passed examination (examination code), passed results of project work (examination code) and group exercises and other compulsory parts (examination code). Possibility to supplement failed compulsory part can be given at the earliest at next course and only in case of a vacancy. Each student has the right to in all six examinations i.e. one examination and five re-examinations.